Israeli firm begins 2nd trial of coronavirus antibody drug

An Israeli company has begun its second trial of a coronavirus antibody drug, after a promising first trial.

The drug, manufactured from antibodies found in the plasma of recovered coronavirus patients and produced by the Kamada pharmaceutical firm, has been administered to 70 patients, according to Zman Yisrael, the Times of Israel’s sister site.


Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed